Leap Therapeutics Inc (LPTX) USD0.001

Sell:$0.29Buy:$0.30$0.01 (4.52%)

Prices delayed by at least 15 minutes
Sell:$0.29
Buy:$0.30
Change:$0.01 (4.52%)
Prices delayed by at least 15 minutes
Sell:$0.29
Buy:$0.30
Change:$0.01 (4.52%)
Prices delayed by at least 15 minutes

Company Information

About this company

Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.

Key people

Christopher K. Mirabelli
Chairman of the Board
Douglas E. Onsi
President, Chief Executive Officer, Director
Augustine J. Lawlor
Chief Operating Officer
Jason Baum
Chief Scientific Officer
Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Mark O'Mahony
Chief Manufacturing Officer
Cynthia Sirard
Chief Medical Officer
Thomas Dietz
Lead Independent Director
James H. Cavanaugh
Independent Director
William W. Li
Independent Director
Joseph Loscalzo
Independent Director
Patricia Martin
Independent Director
Click to see more

Key facts

  • EPIC
    LPTX
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US52187K2006
  • Market cap
    $13.06m
  • Employees
    52
  • Shares in issue
    41.26m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.